retatrutide and heart A study of Lilly's weight loss drug in people with disease did not answer a crucial question — whether it reduces cardiovascular risk Retatrutide and Cardiovascular Risk: Evaluating

Phase 2 trial data reported a mean increase in resting heart rate of approximately 45 beats per minute at higher doses, with some individual variation

GIP Receptor Activation Glucose-dependent insulinotropic polypeptide, abbreviated as GIP, works alongside GLP-1 to enhance insulin response while adding unique benefits for fat metabolism

Doing so helps preserve the compound's structural integrity throughout the dissolution process

Enhancing liver metabolism helping the liver process fat efficiently

The mechanistic advantage of the triple agonist approach is real

For patients paying $300 per year with copay cards, retatrutide is dramatically cheaper than surgery even over 5+ years